Why the study?
Does selexipag improve pulmonary vascular resistance in Japanese patients with pulmonary arterial hypertension?
Does selexipag improve pulmonary vascular resistance in Japanese patients with pulmonary arterial hypertension?
Selexipag significantly improves pulmonary hemodynamics and exercise capacity in Japanese patients with pulmonary arterial hypertension, with a safety profile consistent with other prostacyclin analogs.
Supports selexipag in Japanese PAH patients; extends prior data but leaves open need for Phase 3 confirmation.
BACKGROUND: Selexipag is an orally available prostacyclin receptor (IP receptor) agonist with a non-prostanoid structure. In this open-label Phase II trial, the efficacy and safety of selexipag in Japanese patients with pulmonary arterial hypertension (PAH) is examined. METHODS AND RESULTS: formulations. Thirty-four patients attained the individual maximum tolerated dose (maintenance dose). CONCLUSIONS: The efficacy and tolerability of selexipag in Japanese PAH patients was confirmed by improvement in pulmonary hemodynamics, exercise capacity, symptoms. Selexipag is an efficacious treatment option for Japanese PAH patients. (Trial registration: JAPIC Clinical Trials Information [JapicCTI-111532].).
No takes yet. Share an insight, caveat, or question.
Tanabe et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: